Orlistat and the Influence on Appetite Signals



Intestinal lipase inhibition using orlistat( tetrahydrolipstatin) has been widely used in the pharmacotherapy of morbid obesity. By blocking the active site of lipases, orlistat inhibits the hydrolysis of dietary triglycerides (TG) into monoglycerides (MG) and free fatty acids (FFA), and thus reduces the intestinal absorption of these lipolysis products. The formulation of the drug was licensed for the treatment of morbid obesity at the standard prescription dose of 120 mg three times daily prior to a meal. At this dose, orlistat prevents approximately 30% of the total ingested dietary fat from being absorbed. The secretion of gastrointestinal hormones from enteroendocrine cells is primarily controlled by the absorption of nutrients from the gut. Several studies have been conducted investigating the effect of lipase inhibition on the meal-mediated release of enteroendocrine hormones and regulation of appetite. Intestinal lipase inhibition by orlistat significantly lowers the postprandial secretion of CCK, GLP-1, PYY, PP, and GIP. Conversely, several groups have suggested that orlistat administration prevents the postprandial decrease in ghrelin levels. Leptin levels are only indirectly affected by orlistat treatment through its weight-lowering potential. Taken together, these alterations in gastrointestinal hormone concentrations can cause increased appetite sensations and greater food consumption and may therefore counteract the weight-lowering effect of orlistat.


Ghrelin Level Pancreatic Polypeptide Gastric Inhibitory Polypeptide Lipase Inhibition Gallbladder Emptying 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Agouti-related peptide


Alpha-melanocyte-stimulating hormone

Apo A-IV

Apolipoprotein A-IV


Body mass index


Bombesin/bombesin-related peptide


Cocaine- and amphetamine-regulated transcript




CCK-1 receptor


Central nervous system


Corticotropin-releasing factor




Free fatty acid


Growth hormone-releasing hormone


Growth hormone secretagogue




Gastric inhibitory polypeptide


Gastric inhibitory polypeptide receptor


Glucagons-like peptide 1


Glucagon-like peptide 2


Kilo joule


Melanin-concentrating hormone




Neuropeptide Y


Otsuka-Long-Evans-Tokushima-Fatty rat




Pancreatic polypeptide




Peptide YY






Visual analogue scales



Juris J. Meier and Wolfgang E. Schmidt are acknowledged for helpful comments and critical discussion of the manuscript.


  1. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650–4.PubMedCrossRefGoogle Scholar
  2. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. To eat or not to eat - how the gut talks to the brain. N Engl J Med. 2003;349:926–8.CrossRefGoogle Scholar
  3. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88:3989–92.PubMedCrossRefGoogle Scholar
  4. Beysen C, Karpe F, Fielding BA, Clark A, Levy JC, Frayn KN. Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia. 2002;45:1533–41.PubMedCrossRefGoogle Scholar
  5. Borovicka J, Schwizer W, Guttmann G, Hartmann D, Kosinski M, Wastiel C, Bischoff-Delaloye A, Fried M. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut. 2000;46:774–81.PubMedCrossRefGoogle Scholar
  6. Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab. 2004;89:1319–24.PubMedCrossRefGoogle Scholar
  7. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci. 2006;361:1187–209.PubMedCrossRefGoogle Scholar
  8. Creutzfeld W, Ebert R, Willms B, Frerichs H, Brown JC. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia. 1978;14:15–24.CrossRefGoogle Scholar
  9. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse KE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–19.PubMedCrossRefGoogle Scholar
  10. Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care. 2004;27:1077–80.PubMedCrossRefGoogle Scholar
  11. Daousi C, Wilding JP, Aditya S, Durham BH, Cleator J, Pinkney JH, Ranganath LR. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol. 2009;71:195–201.Google Scholar
  12. Degen L, Drewe J, Piccoli F, Gräni K, Oesch S, Bunea R, D’Amato M, Beglinger C. Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1391–9.PubMedCrossRefGoogle Scholar
  13. Dimitrov D, Bohchelian H, Koeva L. Effect of orlistat on plasma leptin levels and risk factors for the metabolic syndrome. Metab Syndr Relat Disord. 2005;3:122–9.PubMedCrossRefGoogle Scholar
  14. Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, Schmitz F, Meier JJ. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab. 2008;93:3995–8.PubMedCrossRefGoogle Scholar
  15. Enc FY, Ones T, Akin HL, Dede F, Turoglu HAT, Ulfer G, Bekiroglu N, Haklar G, Rehfeld JF, Holst JJ, Ulusoy NB, Imeryüz N. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am J Physiol Gastrointestinal Liver Physiol. 2009;296:G482–9.CrossRefGoogle Scholar
  16. Feinle C, Rades T, Otto B, Fried M. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology 2001;120:1100–7.PubMedCrossRefGoogle Scholar
  17. Feinle C, O’Donovan D, Doran S, Andrews JM, Wishart J, Chapman I, Horowitz M. Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans. Am J Physiol Gastrointest Liver Physiol. 2003;284:G798–807.PubMedGoogle Scholar
  18. Feinle-Bisset C, Patterson M, Ghatei MA, Bloom SR, Horowitz M. Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab. 2005;289:E948–53.PubMedCrossRefGoogle Scholar
  19. Figlewicz DP, Nadzan AM, Sipolis AJ, Green PK, Liddle RA, Porte D Jr, Woods SC. Intraventricular CCK-8 reduces single meal size in the baboon by interaction with type-A CCK receptors. Am J Physiol. 1992;263:R863–7.PubMedGoogle Scholar
  20. Flint A, Raben A, astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–20.PubMedCrossRefGoogle Scholar
  21. Fujimoto S, Inui A, Kiyota N, Seki W, Koide K, Takamiya S, Uemoto M, Nakajima Y, Baba S, Kasgua M. Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol Psychiatry. 1997;41:1068–70.PubMedCrossRefGoogle Scholar
  22. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol. 1973;84:488–95.PubMedCrossRefGoogle Scholar
  23. Glaser B, Zoghlin G, Pienta K, Vinik AI. Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Horm Metab Res. 1988;20:288–92.PubMedCrossRefGoogle Scholar
  24. Goedecke JH, Barsdorf M, Beglinger C, Levitt NS, Lambert EV. Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord. 2003;27:1479–85.PubMedCrossRefGoogle Scholar
  25. Gomez G, Udupi V, Greeley GH Jr. Comparison of somatostatin and pancreastatin on secretion of gastrin, pancreatic polypeptide, and peptide YY. Proc Soc Exp Biol Med. 1997;215:165–7.PubMedGoogle Scholar
  26. Greenman Y, Golani N, Gilad S, Yaron M, Limor R, Stern N. Ghrelin secretion is modulated in a nutrient- and gender-specific manner. Clin Endocrinol. 2004;60:382–8.CrossRefGoogle Scholar
  27. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541–4.PubMedGoogle Scholar
  28. Haluzik M, Papezova M, Nedvidkova J, Kabrt J. Serum leptin levels in patients with anorexia nervosa before and after partial refeeding, relationships to serum lipids and biochemical nutritional parameters. Physiol Res. 1999;48:197–202.PubMedGoogle Scholar
  29. Hildebrand P, Petrig C, Burckhardt B, Ketterer S, Lengsfeld H, Fleury A, Hadvary P, Beglinger C. Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release. Gastroenterology. 1998;114:123–9.PubMedCrossRefGoogle Scholar
  30. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care. 2004;27:33–40.PubMedCrossRefGoogle Scholar
  31. Kissileff HR, Carretta JC, Geliebter A, Pi-Sunyer FX. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol. 2003;285:R992–8.PubMedGoogle Scholar
  32. Koop I, Ruppert-Seipp G, Koop H, Schafmayer A, Arnold R. Cholecystokinin release by gastric distension--an atropine-sensitive mechanism. Digestion. 1990;46:220–7.PubMedCrossRefGoogle Scholar
  33. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77:257–70.PubMedCrossRefGoogle Scholar
  34. Le Roux CW, Ghatei MA, Gibbs JS, Bloom SR. The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart 2005;91:241–2.PubMedCrossRefGoogle Scholar
  35. Lin HC, Taylor IL. Release of peptide YY by fat in the proximal but not distal gut depends on an atropine-sensitive cholinergic pathway. Regul Pept. 2004;117:73–6.PubMedCrossRefGoogle Scholar
  36. Lucas KH, Kaplan-Machlis B. Orlistat--a novel weight loss therapy. Ann Pharmacother. 2001;35:314–28.PubMedCrossRefGoogle Scholar
  37. Mathus-Vliegen EM, Van Ierland-van Leeuwen ML, Terpstra A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. Aliment Pharamcol Ther. 2004;19:601–11.CrossRefGoogle Scholar
  38. Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, D`Amato M, Rovati L, Beglinger C. The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans. Gut. 2000; 46: 688-93.Google Scholar
  39. Meguro T, Shimosegawa T, Kikuchi Y, Koizuma M, Toyota T. Effects of cisapride on gallbladder emptying and pancreatic polypeptide and cholecystokinin. J Gastroenterol. 1995;30:237–43.PubMedCrossRefGoogle Scholar
  40. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91–117.PubMedCrossRefGoogle Scholar
  41. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisite. Regul Pept. 2002;107:1–13.PubMedCrossRefGoogle Scholar
  42. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005;54:2212–8.PubMedCrossRefGoogle Scholar
  43. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–42.PubMedCrossRefGoogle Scholar
  44. Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointestinal Liver Physiol. 2004;286:G183–8.CrossRefGoogle Scholar
  45. Moran TH, McHugh PR. Gastric and nongastric mechanisms for satiety action of cholecystokinin. Am J Physiol. 1988;254:R628–32.PubMedGoogle Scholar
  46. Moran TH, Ameglio PJ, Schwartz GJ, McHugh PR. Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am J Physiol. 1992;262:R46–50.PubMedGoogle Scholar
  47. Murakami N, Hayashida T, Kuroiwa T, Nakahara K, Ida T, Mondal MS, Nakazato M, Kojima M, Kangawa K. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol. 2002;174:283–8.PubMedCrossRefGoogle Scholar
  48. O’Donovan D, Feinle-Bisset C, Wishart J, Horowitz M. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. Br J Nutr. 2003;90:849–52.PubMedCrossRefGoogle Scholar
  49. O’Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilcore D, Wishart JM, Morris HA, Jones KL. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia. 2004;47:2208–14.PubMedCrossRefGoogle Scholar
  50. Onaga T, Zabielski R, Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides 2002;23:279–90.PubMedCrossRefGoogle Scholar
  51. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535–9.PubMedCrossRefGoogle Scholar
  52. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437–46.PubMedCrossRefGoogle Scholar
  53. Peters JH, McKay BM, Simasko SM, Ritter RC. Leptin-induced satiation mediated by abdominal vagal afferents. Am J Physiol Regul Integr Comp Physiol. 2005;288:R879–84.PubMedCrossRefGoogle Scholar
  54. Pilichiewicz A, O’Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:3829–34.PubMedCrossRefGoogle Scholar
  55. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav. 1982;29:627–30.PubMedCrossRefGoogle Scholar
  56. Sahin M, Tanaci N, Yucel M, Kutlu M, Tutuncu NB, Pamuk B, Guvener ND. Acute effects of orlistat on postprandial serum leptin levels in nondiabetic obese patients. Minerva Endocrinol. 2008;33:169–73.PubMedGoogle Scholar
  57. Schwartz GJ, Whitney A, Skoglund C, Castonguay TW, Moran TH. Decreased responsiveness to dietary fat in Otsuka Long-Evans Tokushima fatty rats lacking CCK-A receptors. Am J Physiol. 1999;277:R1144–51.PubMedGoogle Scholar
  58. Svendsen M, Rissanen A, Richelsen B, Rössnr S, Hansson F, Tonstad S. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring). 2008;16:327–33.CrossRefGoogle Scholar
  59. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.PubMedCrossRefGoogle Scholar
  60. Track NS, McLeod RS, Mee AV. Can J Physiol Pharmacol. 1980;58:1484–9.PubMedGoogle Scholar
  61. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86:4382–9.PubMedCrossRefGoogle Scholar
  62. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Endocrinology 2003;144:5184–7.PubMedCrossRefGoogle Scholar
  63. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007;132:2116–30.PubMedCrossRefGoogle Scholar
  64. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel NJ. Retrospective population-based analysis of the dose-response (fecal fat excreation) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56:82–5.PubMedCrossRefGoogle Scholar
  65. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol. 1999;39:41–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Medicine IUniversity Hospital Schleswig HolsteinKielGermany

Personalised recommendations